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The glucose-6-phosphatase catalytic subunit 3 (G6PC3) encodes a ubiquitously expressed enzyme
that regulates cytoplasmic glucose availability. Loss-of-function biallelic G6PC3 mutations cause
severe congenital neutropenia and a diverse spectrum of extra-hematological manifestations,
among which inflammatory bowel disease (IBD) has been anecdotally reported. Neutrophil func-
tion and clinical response to granulocyte colony-stimulating factor (G-CSF) and hematopoi-
etic stem cell transplantation (HSCT) were investigated in 4 children with G6PC3 deficiency-
associated IBD. G6PC3 deficiency was associated with early-onset IBD refractory to treatment
with steroids and infliximab. The symptoms of IBD progressed despite G-CSF treatment. In vitro
studies on the patients’ blood showed that neutrophils displayed higher levels of activationmark-
ers (CD11b,CD66b, andCD14), excessive IL-8 and reactive oxygen species, and increased apopto-
sis and secondary necrosis. Secondary necrosiswas exaggerated after stimulationwith Escherichia
coli and could be partially rescued with supplemental exogenous glucose. HSCT led to normaliza-
tion of neutrophil function and remission of gastrointestinal symptoms. We conclude that neu-
trophils in G6PC3 deficiency release pro-inflammatory mediators when exposed to gut bacteria,
associated with intestinal inflammation, despite treatment with G-CSF. HSCT is an effective ther-
apeutic option in patients with G6PC3 deficiency-associated IBD refractory to immune suppres-
sants.
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1 INTRODUCTION
Autoinflammation is a recognized feature of primary immuno-
deficiencies.1 One example is inflammatory bowel disease (IBD)
Abbreviations: AIHA, autoimmune hemolytic anemia; ANC, absolute neutrophil count; ATCC, American Type Culture Collection; CGD, chronic granulomatous disease; CMV, cytomegalovirus;
DNA, deoxyribonucleic acid; DHR, dihydrorhodamine; FDR, false discovery rate; fMLP, N-formyl-methionyl-leucyl-phenylalanine; G6PC3, glucose-6-phosphatase catalytic subunit 3; G-CSF,
granulocyte colony-stimulating factor; GvHD, graft versus host disease; HSCT, hematopoietic stem cell transplantation; IBD, inflammatory bowel disease;MFI, geometric mean fluorescence
intensity; MSD, matched sibling donor; MUD,matched unrelated donor; PCR, polymerase chain reaction; PDCAI, Pediatric Crohn’s Disease Activity Index; PMA, phorbol 12-myristate 13-acetate;
RNA, ribonucleic acid; ROS, reactive oxygen species; RPMI, Roswell ParkMemorial Institute; SCN, severe congenital neutropenia.
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associated with severe congenital neutropenia (SCN) caused by
glucose-6-phosphatase catalytic subunit 3 (G6PC3) deficiency.2–11
Case reports suggest that G6PC3 deficiency-associated IBD can
be complicated by progressive intestinal inflammation refractory
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to medical treatment and often requires surgery.2–11 Improving
clinical outcomes for affected patients depends on understanding the
underlying diseasemechanisms, which are currently unknown.
G6PC3 deficiency is caused by biallelic loss-of-function variants in
G6PC3, which encodes glucose-6-phosphatase-𝛽 (G6Pase-𝛽), a ubiq-
uitously expressed enzyme that regulates cytoplasmic glucose avail-
ability through hydrolysis of glucose-6-phosphate during glycolysis
and glycogenolysis.12 As well as SCN, G6PC3 is associated with
a diverse spectrum of extra-hematological manifestations, including
cardiac and urogenital abnormalities.12 G6PC3 deficiency results in
neutropenia because neutrophils are highly dependent on glycolysis
as an energy source.13,14 Studies in humans and mice with G6PC3
deficiency have demonstrated neutrophil dysfunction characterized
by accelerated apoptosis.10,15–17 However, IBD is not a feature of
other SCNs that also demonstrate accelerated neutrophil apoptosis.18
This suggests a mechanism independent of apoptosis underpins IBD
in G6PC3 deficiency.
Treatment with G-CSF normalizes peripheral neutrophil count and
reduces the risk of neutropenic infections, but it is not known if it pro-
motes G6PC3 deficiency-associated IBD.12,18
Here,wedescribe4 childrenwithG6PC3deficiency-associated IBD
and neutrophil dysfunction characterized by excessive production of
pro-inflammatory mediators and increased necrosis. Hematopoietic
stemcell transplant (HSCT)was performed in 3 children and led to nor-
malizationof neutrophil function and remissionof IBD, and thus should
beconsideredas a therapeutic option for refractoryG6PC3deficiency-
associated IBD.
2 MATERIALS AND METHODS
2.1 Participants
The research protocol was approved by the NHS Research Ethics
Committee (Reference 14/SW/0100). Written informed consent was
obtained from healthy volunteer adult controls and the parents/legal
guardians of children with G6PC3 deficiency. Venipuncture was
deferred if therewas history of febrile illness or active IBD flarewithin
the preceding 14 days.
2.2 Cell culture
Cells were isolated by negative immunomagnetic selection within 1 h
of venipuncture by EasySep Neutrophil or Monocyte Direct Isola-
tion kits (STEMCELL Technologies). Neutrophils were incubated at
37◦C/5%CO2 with gentle rocking in triplicate sterile 5mL polystyrene
tubes at 0.5 × 106 cells/ml in Roswell Park Memorial Institute
(RPMI) 1640 medium (Sigma-Aldrich) containing 10% autologous
serum. Monocytes were incubated in triplicate tissue culture wells at
37◦C/5%CO2 at 0.5 × 106 cells/ml in RPMImedium/10% FCS.
2.3 Bacteria
Escherichia coli American Type Culture Collection (ATCC) 25922 (gift
from Professor Ian Roberts, University of Manchester) were grown in
lysogeny brothmedium (Thermo Fisher) at 37◦Cand harvested inmid-
log phase.
2.4 Flow cytometry
Neutrophils were incubated with Fc receptor blocking solution
(TruStain FcX, BioLegend) and then the appropriate Ab cocktail at 4◦C
for 20 min. In cell death assays, TO-PRO 3 (Thermo Fisher) was added
for the final 5 min of incubation. After washing, at least 100,000 cells
were acquired on a BD Fortessa cytometer (immunophenotyping)
or BD FACS Canto-II cytometer (cell death and reactive oxygen
species). Single stain controls were prepared using compensation
beads (OneComp, Thermo Fisher). Samples were analyzed after
compensation was set using FlowJo (Version 10.3, FlowJo LLC) and
gating determined using the fluorescence-minus-one principle.
2.5 Solublemediatormeasurement
After thawing culture supernatants from -80◦C, cytokines were quan-
tified by multiplex bead array (Soluble Protein Human Flex Set, BD
Biosciences) and acquired on a BD FACSVerse system, with analysis
by FCAP Array (Version 3.0, Soft Flow Inc.). Neutrophil elastase and
MMP-9were quantified by sandwich ELISA (Abcam). Lactate dehydro-
genasewasmeasuredby theCytoTox96Non-RadioactiveCytotoxicity
Assay (Promega).
2.6 Measurement of RNA expression
Cells were disrupted by buffer RLT (QIAGEN) and ribonucleic acid
(RNA) isolated using RNeasy Micro Kit (QIAGEN). RNA yield and
purity were measured on the Nanodrop 2000c system (Thermo
Fisher), and reverse transcribed (high-capacity RNA-to-cDNA kit,
Applied Biosystems). Quantitative real-time polymerase chain reac-
tion (PCR) was performed on duplicate cDNA samples using Taqman
primers andMaster Mix on a Quantstudio 12K System (Life Technolo-
gies). Relative RNA expression was calculated to the mean expression
of 2 housekeeping genes (RPLP0 and ACTB) and fold-change calculated
relative to an unstimulated sample.
2.7 Statistical analysis
Statistical analysiswas undertaken using Prism (Version 7.0, GraphPad
Software). Variability between technical replicates was analyzed
by calculation of the coefficient of variation (CVV). Parametric dis-
tribution of the data was confirmed by the Shapiro-Wilk normality
test. Comparisons were made using the Student’s t-test with Welch’s
correction for unpaired data, with control of False Discovery Rate
(FDR) by the Benjamini-Hochberg method where appropriate. When
more than 2 groups were compared, significance was determined by a
1-way ANOVA with Bonferroni’s correction for multiple comparisons.
Dependent variables that were measured more than once were ana-
lyzed by a 1-way repeated measures ANOVA with Dunnett’s multiple
comparisons test. The significance levels were set at P < 0.05 and
FDR< 0.05.
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F IGURE 1 Clinical phenotypeof IBD inG6PC3deficiency. (A)Daily stool frequencyofP3 fordays followingweeklypegylatedG-CSF injections.
Line represents median of observations taken over a 6-week period. Statistical significancewas determined by 1-way ANOVAwith Dunnett’s mul-
tiple comparisons test. **P < 0.01. (B) Colonoscopy image from P1 demonstrating severe mucosal ulceration and sloughing. (C) Intestinal biopsies
(H&E, 400×) demonstrating marked cryptitis with neutrophilic inflammatory infiltrate in the lamina propria in P1 (right) and idiopathic Crohn’s
disease (center). Images presented in comparison with biopsy from a healthy individual (left)
3 RESULTS AND DISCUSSION
Four patients (P1-P4) with G6PC3 deficiency aged 7–21 years were
studied. All suffered from chronic debilitating diarrhea beginning
in early infancy, as well as severe recurrent lower respiratory tract
infections. Following the diagnosis of constitutional neutropenia at
the age of 2 days–10 years old, all patients were commenced on
subcutaneous G-CSF treatment. Bone marrow aspirate and trephine
demonstrated a paucity of mature neutrophils, or normal cellu-
larity with no maturation arrest. One patient (P1) exhibited other
immunophenotypic abnormalities including CD4+ T cell lymphopenia
and a low serum IgG level (Supplemental Table 1). Homozygous
variants in G6PC3 were identified in all 4 patients (Supplemental Fig.
1). In 2 patients, mutations were truncating (P1: c.282delA and P2:
c.882_903dup) and predicted to be more deleterious and were associ-
atedwith amore severe pattern of extra-hematologicalmanifestations
(Supplemental Table 1). Stools were described as watery, with episodic
exacerbations characterized by bloody diarrhea, abdominal pain, and
malaise. Diarrhea impacted the patients’ quality of life, causing waking
from sleep and school absences. No pathogens were detected by
microscopy, bacterial culture, or PCR. Gut histology from P1 and P2
showed no granulomata. However, there were diffuse inflammatory
changes in the stomach, duodenum, terminal ileum, and particularly
colon that was most severe, with cryptitis, crypt abscesses, and focal
ulceration (Fig. 1B andC). In somebiopsies, foamyM𝜙swere observed,
which can be seen in chronic granulomatous disease (CGD). Pediatric
Crohn’s Disease Activity Index (PDCAI) suggested moderate-severe
disease, except P4 who had mild disease (Supplemental Table 2).19
P3 and P4 did not require endoscopic evaluation. The colitis was
poorly responsive to prednisolone in patients P1-P3 and azathioprine,
sulfasalazine, and infliximab in patients P1 and P2.
Both amelioration5,7 and deterioration2,8 of enteritis has been
described following the commencement of G-CSF therapy in patients
with G6PC3 deficiency. In all our patients, severity of the diarrhea
increased following the initiation of G-CSF therapy, except P1 who
had commenced treatment in the neonatal period. Absolute neu-
trophil count (ANC) was maintained on a daily G-CSF dose of 3–
10 mcg/kg/day in all patients except P3 who received weekly pegy-
lated G-CSF injections at 120 mcg/kg/week (Supplemental Table 1). In
P3, ANC troughwas 1.7 × 109/L and peak was 9.7 × 109/L 2 days after
pegylated G-CSF injection, which coincided with a significant increase
in stool frequency (Fig. 1A).
HSCT can cure neutropenia and has been recently reported to
ameliorate IBD in an adult with G6PC3 deficiency.11,20 We first
performed HSCT in P4 primarily due to poorly tolerated local and
systemic side effects of G-CSF injections, and the wishes of the
patient and her family, as well as her enteritis (Table 1). We then
performed HSCT on P2 and P3 for treatment-refractory enteritis
(Table 1). P1 is currently scheduled for HSCT. Conditioning consisted
of a standard reduced toxicity regimen including in vivo T cell deple-
tion with alemtuzumab for prevention of graft versus host disease
(GvHD; Table 1). Grafts were from a matched unrelated donor in
1 patient, and sibling donors in the other 2 patients (Table 1). All
patients had high levels of donor engraftment. Post-HSCT, all 3
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TABLE 1 HSCT in G6PC3 deficiency
P1 P2 P3 P4
Current age (years) 7 14 21 18




Indication for HSCT IBD IBD IBD& poorly tolerated
G-CSF
Conditioning regimen TT/Treo/ Flu/Alem TT/Treo/Flu/Alem TT/Treo/Flu/Alem
GvHD prophylaxis Ciclo Ciclo Ciclo
CMVRecipient/Donor +/+ +/+ +/+
EBVRecipient/Donor +/+ +/+ −/−
Graft (donor) MUD MSD MSD
Graft (type, HLAmatch) bmsc 10/10 bmsc, 10/10 bmsc, 10/10
Platelet engraftment
A
(day post-HSCT) 33 41 20
Neutrophil engraftmentB (day post-HSCT) 12 21 13
Lymphocyte engraftmentC (day post-HSCT) 42 42 23
GvHDGrade Nil Nil Nil
VOD Nil Nil Nil
Other significant post-HSCT complications Nil AIHA Nil
Systemic viral infection after day 0 CMV CMV CMV
Latest chimerism (as of end 2019) 100% donor 98% donor 100% donor
A
Platelet count>20 × 109 for 7 consecutive days without need for transfusion;
B
Neutrophil count>0.5× 109 for 3 consecutive days;
C
Lymphocyte count>0.3 × 109;
Abbreviations: IBD, inflammatory bowel disease; GvHD, graft versus host disease; VOD, veno-occlusive disease; TT, thiotepa; Treo, treosulfan (42 g/m2 as a
once daily dose for 3 days); Flu, fludarabine (160 mg/m2 as a once daily dose for 4 days); Alem, alemtuzumab (total 0.3 mg/kg given over 3 days in MSD, and
1mg/kg given over 5 days inMUD, as a once daily dose and completing on day−5); Ciclo, ciclosporin;MUD,matched unrelated donor;MSD,matched sibling
donor; bmsc, bonemarrow stem cells; AIHA, autoimmune hemolytic anemia; CMV, cytomegalovirus.
patients developed subclinical cytomegalovirus (CMV) reactivation,
treated with ganciclovir. In all patients, HSCT was associated with a
remission of gastrointestinal symptoms evidenced by the dramatic
and sustained reduction in PDCAI scores (Supplemental Table 2).
In addition, all are now attending school or university 2–3 years
post-HSCT, with the only residual medical problems being bronchiec-
tasis requiring prophylactic antibiotics (P2 and P4), and gonadal dys-
function requiring hormone replacement (P2 and P3; Supplemental
Table 2).
Given that G-CSF injections were associated with increased stool
frequency and HSCT was associated with remission of gastrointesti-
nal symptoms, we considered whether G6PC3 deficiency-associated
IBDmay be driven by phagocyte dysfunction. As previous studies have
described accelerated neutrophil cell death from patients with G6PC3
deficiency,10,15,16 we hypothesized that this might drive intestinal
inflammation, particularly in the gut where neutrophils are exposed to
commensal microbes.We therefore assessed neutrophil cell death fol-
lowing incubation with live Escherichia coli. Neutrophils from patients
with G6PC3 deficiency underwent significantly more apoptosis and
secondary necrosis, particularly when incubatedwith E. coli, compared
with equivalents from healthy control volunteers (Fig. 2A–C). The pat-
tern of neutrophil death in 1 patient (P4) who had undergone HSCT
was in keeping with the healthy controls.
Accelerated neutrophil death in G6PC3 deficiency has been
attributed to ER and oxidative stress driven by a lack of cytoplasmic
G6P.21 It is therefore possible that increasing the exogenous glucose
to supra-physiological levels might rescue neutrophils from death.
We therefore compared cell death of neutrophils from a patient with
G6PC3 deficiency (P2) and a healthy control, following culture with
increasing concentrations of D-glucose (Fig. 2D). In the complete
absence of exogenous glucose, the median proportion of neutrophils
undergoing secondary necrosis was similar in the patient with G6PC3
deficiency (14%) and the healthy control (16%; Fig. 2D). Increasing
the exogenous glucose concentrations to 1 mM or more led to almost
complete rescue of neutrophils of the healthy donor from necrosis
(2–3% necrotic neutrophils), while only partial rescue (7–8% necrotic
neutrophils) in the patient with G6PC3 deficiency (Fig. 2D). This
observation is consistent with previous studies in neutrophils from
G6PC3−/− mice demonstrating: (i) impaired glucose uptake associated
with impaired GLUT1 translocation to the plasma membrane17;
and (ii) impaired glycolysis caused by failure to destroy an ana-
logue of phosphorylated glucose (1,5-anhydroglucitol-6-phosphate)
that inhibits hexokinases.22 Glucose within the subepithelial space
may thus prevent neutrophil necrosis in healthy individuals but
not in patients with G6PC3 deficiency. This may help explain why
patients with other genetically defined causes of SCN without
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F IGURE 2 Increased neutrophil necrosis in G6PC3 deficiency is exacerbated by stimulationwith live E. coli. (A) Representative flow cytome-
try of neutrophils culturedwithE. coli (ATCC#25922) atMOI1:1 for 1h and stainedwithAnnexinVanda cell impermeant dyeTO-PRO3. Left panel
representative of healthy controls and right panel representative of patientswithG6PC3deficiency. (B) Cell death as ascertained by flow cytomet-
ric measurement of Annexin V and TO-PRO3; (C) LDH release as assessed by colorimetric assay of culture supernatant; (D) Cell death assessed by
staining with Annexin V and TO-PRO 3 from a patient with G6PC3 deficiency (P2) and a healthy control, following an 8 h incubation of neutrophils
in glucose-free RMPI 1640 medium with supplemental exogenous D-glucose at the indicated concentrations in glucose-free RPMI 1640 (results
representative of 2 independent experiments). Data points in (B) and (C) each represent median of 3 separate measurements all with CVV < 12%
performed on single individuals, denoted by circles (patients with G6PC3 deficiency receiving G-CSF therapy, P1●; P2 ;P3○) or squares (P4■ 2
years post-HSCT not receiving G-CSF therapy; and healthy adult controls). Significance determined by Student’s t-test withWelch’s correction
for unpaired datawhere “**” and “***” denote P< 0.01 and< 0.001, respectively (A-C), and 1-wayANOVAwith Bonferroni’s correction formultiple
comparisons where *, **, ***, and **** denote P< 0.05,< 0.01,< 0.001, and< 0.0001, respectively (D)
defective glucose metabolism (e.g., HAX1 deficiency) do not suffer
from IBD.23
Increased necrosis implies that neutrophils in patients with G6PC3
deficiency have an altered inflammatory activation status, or a lower
proportion that are immature.24,25 We tested this theory bymeasuring
expression of neutrophil surface markers.26,27 There was significantly
higher expression of CD14, CD66b, and CD11b on freshly isolated
live neutrophils from patients with G6PC3 deficiency compared with
healthy controls (Supplemental Fig. 2A). There was however no signifi-
cant difference in the expression of CD64, CD16, TREM-1, and CD62L
(Supplemental Fig. 2A) nor the proportion of CD11bhigh/CD16low/-
immature neutrophils (Supplemental Fig. 2B). These observations sug-
gest that neutrophils frompatientswithG6PC3deficiency aremature,
but constitutively activated.
Constitutively activated neutrophils in patients with G6PC3 defi-
ciency could contribute to IBD through excessive release of soluble
inflammatory mediators. We therefore measured soluble inflamma-
tory mediators and found significantly higher IL-8 release, but not
TNF-𝛼, IL-6, and IL-1𝛽 , from the unstimulated neutrophils of patients
with G6PC3 deficiency, compared with healthy controls (Fig. 3A).
Colonic IL-8 levels correlate with IBD severity, as excessive IL-8 drives
tissue inflammation by its action as a potent neutrophil chemoattract
and activation ligand.28,29 We also found significantly lower release of
neutrophil elastase and MMP-9 in E. coli-stimulated neutrophils from
G6PC3 patients comparedwith healthy controls (Fig. 3A).
Dysregulated reactive oxygen species (ROS) production by neu-
trophils is associated with mucosal inflammation, as observed in
colonic resection specimens of IBD patients in which ROS is increased,
and IBD caused by CGD in which ROS is reduced.30,31 We therefore
measured neutrophil ROS production by its oxidation of dihydrorho-
damine (DHR) to rhodamine-123. Phorbol 12-myristate 13-acetate
(PMA)-stimulated neutrophils from patients with G6PC3 deficiency
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F IGURE 3 Dysregulated production of soluble pro-inflammatory mediators in G6PC3 deficiency. (A) Measurement of soluble mediators in
the culture supernatant of neutrophils incubated in media alone or with E. coli (ATCC #25922) at MOI 1:1 for 1 h. TNF-𝛼, IL-8, IL-6, and IL-1𝛽
weremeasured by cytokine bead array. Neutrophil elastase andMMP-9weremeasured by ELISA. (B andC) Assessment of reactive oxygen species
(ROS) production by measurement rhodamine-123 (R-123) fluorescence in neutrophils by flow cytometry after loading with dihydrorhodamine
(25 ng/ml) for 15 min, and incubation (B) PMA (100 ng/ml) for 45 min; or (C) fMLP (1 𝜇M) for 20 min or with (D) culture medium alone. Dihy-
drorhodamine (DHR) index calculated as: PMA-stimulatedMFI/unstimulatedMFI (MFI: geometric mean fluorescence intensity). Data points each
represent median of 3 separate measurements with CVV < 16% performed on single individuals, denoted by circles (patients with G6PC3 defi-
ciency receivingG-CSF therapy, P1●; P2 ; P3○) or squares (P4■ 2 years post-HSCT not receivingG-CSF therapy; and healthy adult controls).
Fluorescence minus one sample denoted by unfilled histogram. Significance determined by Student’s t-test with Welch’s correction for unpaired
data where “*” denoted P< 0.05, and where appropriate control of False Discovery Rate (FDR) by the Benjamini-Hochberg method was applied in
which “*” denotes FDR< 0.05
had a significantly lower DHR index compared with healthy con-
trols (Fig. 3B). Where cellular yield was sufficient, stimulation with
N-formyl-methionyl-leucyl-phenylalanine (fMLP) was also performed
and similar results were observed (Fig. 3C). In contrast, unstimulated
neutrophils from patients with G6PC3 deficiency demonstrated a
significantly higher mean fluorescence intensity of rhodamine-123
comparedwith healthy controls (Fig. 3D). The pattern of inflammatory
mediator production of the patient with G6PC3 deficiency who had
undergone successful HSCT 2 years earlier (P4) closely aligned with
the healthy controls. Collectively these observations suggest that
constitutively activated neutrophils in G6PC3 deficiency produce
excessive pro-inflammatory mediators in steady state conditions but
have a reduced capacity to do so upon stimulation.
Given previous reports of mononuclear phagocyte dysfunc-
tion in G6PC3 deficiency, we considered whether monocyte
dysfunction might also contribute to intestinal inflammation.9,32
We therefore stimulated freshly isolated peripheral monocytes with
LPS and assessed cytokine production and cell death. Under both
media and LPS conditions, there were no significant differences in
innate cytokine production by monocytes from patients with G6PC3
deficiency compared with healthy controls (Supplemental Figure 3).
There were also no significant differences in the RNA expression of
genes involved in regulating apoptosis or LDH production from the
monocytes of patients compared with healthy controls (Supplemental
Figure 3). Therefore, defective function of peripheral phagocytes in
G6PC3 deficiency appears restricted to neutrophils.
For the first time, we show that neutrophils from patients with
G6PC3 deficiency exhibit elevated constitutive expression of inflam-
matory cell surface markers (CD11b, CD66b, and CD14), cytokines
(IL-8), and ROS reflecting an intrinsically higher inflammatory
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activation state of neutrophils in G6PC3 deficiency, possibly because
neutrophils are particularly dependent on glycolysis as an energy
source.13,14 Reduced release of neutrophil elastase and MMP-9 from
G6PC3 deficient neutrophils suggests a defect in degranulation, which
could be tested in future studies. It is unlikely that the observed
differences were caused by G-CSF treatment rather than G6PC3 defi-
ciency, as previous studies have demonstrated that G-CSF treatment
is associated with reduced apoptosis, normal ROS production and
changes in surfacemarker expression that return to normal after a few
days treatment.33–35
An important limitation of our study was the small number of
participants and therefore it would be useful if our findings were
confirmed in larger independent studies. We were unable to recruit
more patients with G6PC3 due to the rarity of the condition, and the
necessity to perform functional neutrophil studies on freshly drawn
blood. Nonetheless, our data highlight that early-onset IBD can be a
major complication of G6PC3 deficiency associated with significant
morbidity. Gastrointestinal symptoms were more severe in patients
with genotypes predicted to be more deleterious. Three patients
successfully underwent HSCT, associated with complete remission of
their IBD. Post-HSCT, neutrophil responses closely aligned with those
of healthy controls. We therefore conclude that G6Pase-𝛽 (and there-
fore cytoplasmic glucose availability in neutrophils) has an important
role in mucosal immunity and increased neutrophil inflammatory
output may drive enteritis in patients with G6PC3 deficiency. Future
studies should seek to test whether G6PC3 deficiency-associated IBD
can be ameliorated by rescuing neutrophils from death, by lowering
1,5-anhydroglucitol-6-phosphate levels with therapeutic inhibitors of
the kidney glucose transporter SGLT2.22 In the interim, we propose
that clinicians check for IBD in patients with G6PC3 deficiency and
consider HSCTwhen IBD is difficult to control.
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